A new spin-out company, Cambridge Simulation Solutions Limited, has been formed to exploit the technology developed by Dr Vassilios Vassiliadis, a Senior Lecturer in this Department. Dr Vassiliadis has developed a method to simulate and control complex chemical processes.
Dr Vassiliadis, said, "The aim of Cambridge Simulation is to produce a rapid integrator engine suitable for a range of applications and industries, including Chemical Engineering, Biotechnology, Biomedical, Pharmaceuticals, Aerospace and Microelectronics."
Frontier IP, which specialises in the commercialisation of university intellectual property, has entered into an agreement with Cambridge Simulation in which it provides advisory and business development services in return for a stake in the new spin-out. Frontier IP's role will be to support the licensing and commercialisation of this technology, which potentially has a wide range of commercial applications in industry, including the food and pharmaceutical sectors.
Neil Crabb, Chief Executive of Frontier IP, said, "This collaboration with Dr Vassilios Vassiliadis represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising IP and we look forward to working with Dr Vassiliadis and the Department of Chemical Engineering and Biotechnology at the University of Cambridge to maximise the potential of the existing and the upcoming IP."
Professor Nigel Slater, Head of Department, said, "The Department of Chemical Engineering and Biotechnology at the University of Cambridge fuses leading-edge biotechnology research with chemical engineering skills within an ethos of commercial awareness and exploitation. Broadly, our research strategy targets sustainable reaction engineering, product engineering and healthcare and the Department's activities are structured to provide novel solutions to these challenges. I welcome the launch of this company, as an example of the Department's innovative spirit in tackling the issues of our time."